Vivek Subbiah: Fantastic meeting with amazing leaders from Virginia Oncology Associates
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Absolutely thrilled to have had a fantastic meeting and enriching discussion with our amazing leaders from Virginia Oncology Associates.
Dr. Mark Fleming, President VOA, Disease Chair, GU Cancer Research Executive Committee SCRI and Dr. Michael Danso, Executive Member Breast Cancer Research Executive Committee and Bridge Program SCRI.
Our collaboration is pivotal in delivering novel drugs and groundbreaking clinical trials to patients within their local communities.
Looking forward to the impactful work we will achieve together!”
More posts featuring Vivek Subbiah.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023